Toll-like Receptors Signaling Pathways as a Potential Therapeutic Target in Cardiovascular Disease

Author(s): Seyed Mostafa Parizadeh, Maryam Ghandehari, Motahareh Heydari-majd, Sima Seifi, Ramin Mardani, Seyed Mohamadreza Parizadeh, Majid Ghayour-Mobarhan, Gordon A. Ferns, Seyed Mahdi Hassanian*, Amir Avan*.

Journal Name: Current Pharmaceutical Design

Volume 24 , Issue 17 , 2018

Become EABM
Become Reviewer

Abstract:

Cardiovascular Disease (CVD) is one of the most important causes of morbidity and mortality, and associated with an important economic burden globally. Over the last decade, the prevalence of CVD has been rising globally, and is now associated with millions of death annually in both developed and developing countries. There is good evidence that the immune system is involved in the pathophysiology of CVD. Toll-like receptors (TLRs) and their down-stream signaling pathways play an important role in the immune system. Recent studies have suggested that the TLRs are involved in atherogenesis, including stroke, myocardial infarction, ischemiareperfusion injury, cardiac remodeling and development of Heart Failure (HF). In this review we have summarized the recent studies investigating the role of TLRs in CVD and the potential for using TLRs signaling pathways as a therapeutic target in CVD.

Keywords: Cardiovascular disease, immune system, Toll-like receptors, signaling pathway, atherogenesis, stroke.

Rights & PermissionsPrintExport Cite as

Article Details

VOLUME: 24
ISSUE: 17
Year: 2018
Page: [1887 - 1898]
Pages: 12
DOI: 10.2174/1381612824666180614090224
Price: $58

Article Metrics

PDF: 19
HTML: 4